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ABSTRACT 
 
The influence of chitosan on the degradation characteristics of paclitaxel-loaded Poly 
(Lactic-co-Glycolic Acid) (PLGA) rod-shaped implants was investigated and modeled. The 
implant was designed for sustained release of the hydrophobic chemotherapeutic paclitaxel 
(PTX) intramuscularly or subcutaneously. In this study, integration of PTX and PLGA was 
achieved via a solvent evaporation method resulting in a solid dispersion of the substances. To 
customize degradation of the implants and secure delivery of high doses of PTX, chitosan and 
the PLGA-PTX blend were mixed in a 30:70 mass ratio. Cryomilling was utilized to create the 
chitosan-PLGA-PTX mixture, due to its proven effectiveness in producing homogenous blends. 
Implants were then fabricated into rods by injection molding and characterized in terms of 
content uniformity, morphology, and thermal property. The integrity of the blends was 
ascertained via x-ray diffraction, while miscibility between the drug and excipients was 
established by differential scanning calorimetry. In vitro drug release was studied in a phosphate 
buffer of pH 7.4 and measured by ultraviolet-visible spectrophotometry (UV-Vis). Meanwhile, 
the degradation rate was determined by quantifying mass loss at various points in 30 days. This 
study revealed the chitosan blended PTX-loaded PLGA implant possesses a longer, yet steadier, 
sustained drug release behavior than the PTX-loaded PLGA implant. The results suggest that 
introducing chitosan into PLGA implants through this fabrication method could be integrated to 
regulate and control the degradation rate of PLGA implants. 
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CHAPTER 1                                                                                                                  
GENERAL INTRODUCTION 
 
Paclitaxel is an antimicrotubule agent approved for the treatment of various cancers, 
including breast, ovarian, head, and neck cancers [1-3]. Although traditional, infusion-based, 
paclitaxel therapy is effective, there are problems associated with the systemic delivery of high 
doses of paclitaxel that fail to provide a desired drug concentration to localized tumors. For 
instance, due to paclitaxel's hydrophobic nature, the current commercial aqueous solution is 
composed of Cremophor EL and ethanol, which may trigger or aggravate side effects, such as 
nephrotoxicity, induce hypersensitivity reaction, and neurotoxicity [4, 5]. Hence, a more 
appropriate drug delivery system is needed to not only achieve lower toxicity chemotherapy in 
comparison to conventional infusion methods, but also to provide a sustained-release of 
chemotherapeutics to the human body. 
Incorporating drugs into biodegradable polymers for their delivery is one of the most 
widely used methods in current pharmaceutical science research [6]. The basic concept of this 
method is to maintain the drug’s concentration in body fluids over a long time by releasing the 
drug from the degraded polymers. Moreover, as a promising approach for delivery of most 
drugs, polymeric drug delivery systems have the following advantages: (1) there are abundant 
biocompatible polymers available, not to mention a plethora of modified or hybrid biopolymers 
and synthetic polymers; and (2) various forms of drug carriers made by polymers are available 
for processing, such as nano/micro particles, hydrogels, micelles, films, wafers, and foams. 
So far, various polymeric drug delivery systems have been demonstrated to considerably 
enhance the therapeutic efficacy of paclitaxel according to previous research [5, 7-12]. However, 
there are some limitations and drawbacks associated with these methods. First, for certain 
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applications, the safety of the materials used during the complicated preparations, such as 
organic solvents and crosslinking agents [13], needs verification because traces of these 
substances may remain in the final products, and could be harmful to the human body. Second, 
the initial burst effect is a typical issue for most micro/nano particle systems [5] and micelles [9]. 
Lastly, for bulky implants, e.g., films, tablets, and wafers, surgical implantation is inevitable. 
To overcome or avoid these common problems, this study proposed a different 
approachable polymeric drug delivery system for paclitaxel, a biodegradable polymer-based, 
rod-shaped implant. The rod-shape geometry of the proposed implant provides the advantage of 
allowing the implant to be easily placed into the human body subcutaneously or intramuscularly 
by insertion or surgical incision. In comparison, Norplant, also a rod-shaped implant has been 
marketed in the United States since 1991 and proven effective as an approach for contraception 
[14]. Another benefit of the rod-shaped design is that it can be fabricated using a common 
manufacturing method—injection molding—that can be more adequate for bulk fabrication. 
Therefore, in this study, biodegradable polymers were chosen to constitute the rod-shaped 
implant to provide sustained drug release. 
PLGA, a synthetic polymer composed by poly lactic acid (PLA) and poly glycolic acid 
(PGA) [15], is one of the FDA-approved biodegradable polymers. It has been extensively used in 
biomaterials applications, especially in drug delivery systems [16]. Many studies have indicated 
PLGA has great biocompatibility and biodegradability as a drug delivery carrier for paclitaxel in 
the form of micro/nano particles [4, 7, 17, 18], foams [12], films [19], electrospun fibers [20], 
and hydrogels [21]. But, limited work has been completed on PLGA-based, rod-shaped implants 
for sustained release of paclitaxel. Preferably, the low glass transition temperature of PLGA 
makes it easy to process through injection molding. However, there are some minor problems 
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associated with the degradation of polymers composed of PGA or/and PLA in the human body 
[22, 23] These problems include (1) the degradation mechanism of PLGA, which degrades by 
bulk erosion, and it is not ideal for drug release since the erosion rate is difficult to control. (2) 
PLGA degradation yields acidic products, lactic acid and glycolic acid, which may increase the 
risk of inflammation at the implant site [22, 23]. 
To circumvent these issues, chitosan was selected to be added to the implant. Chitosan is 
one of the most abundant natural polymers in the world, and its characteristic biocompatibility 
and biodegradability makes it very attractive and practical in their use for biomedical 
applications [6, 23-34], including drug delivery systems [35], wound dressings [27], and artificial 
tissue/organ implants [26, 36]. In fact, several biomaterial applications composed of PLGA and 
chitosan have been reported previously. Chakravarthi and Robinson confirmed chitosan-PLGA 
particles are able to enhance the cellular association and cytotoxicity of paclitaxel [37]. 
However, blending Chitosan with PLGA to produce a bulk implant for delivery of paclitaxel has 
not been reported previously. According to the results from the work achieved by Wang et al. 
[30], the hybrid matrix composed by 70%w/w PGA and 30%w/w Chitosan was established as a 
new biomaterial with good mechanical properties and degradability. Therefore, a 30% weight 
ratio of chitosan to the whole implant was chosen for this study. Comparisons were made among 
PLGA rods, 10%w/w PTX loaded PLGA rods, 30%w/w chitosan loaded PLGA rods, and 
10%w/w PTX - 30%w/w Chitosan loaded PLGA rods with regards to degradability on in vitro 
studies. 
In this work, limited by the nature of chitosan—e.g., insoluble in most common organic 
solvents and water, rigid, brittle, and thermal sensitive—the method to blend chitosan with 
paclitaxel loaded PLGA was narrowed to cryogenic milling. Cryomilling, a variation of 
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mechanical milling under cryogenic temperatures, has become an effective technique to 
pulverize and blend substances, including polymers and metals [38]. Several articles have 
focused on the use of cryomilling to fabricate biodegradable scaffolds comprised of immiscible 
polymers to avoid undesirable chemical reactions, unstable morphologies, and unwanted 
polymer degradation caused by melt blending or use of harmful solvents [39, 40]. Followed by 
cryomilling, injection molding was applied in this work to process the mixed powders into the 
final products—rod-shaped implants.  
The integrity of the blends was ascertained via x-ray diffraction. The miscibility between 
the drug and excipients was evaluated via differential scanning calorimeter. An in vitro 
experiment was performed to investigate the influence of chitosan on implant degradation 
behavior. Since erosion is the main mechanism that releases paclitaxel from biodegradable 
implants [5], the mass loss profile was utilized to determine the implant drug release rate. 
Meanwhile, the pH of the degradation medium was measured at fixed time points to investigate 
the differences in degradation among the implants.  
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CHAPTER 2                                                                                                           
LITERATURE REVIEW 
 
This review of literature is divided into four parts: (1) chemotherapeutics, (2) drug 
delivery systems, (3) biomaterials, (4) manufacturing processes for drug delivery systems. 
 
2.1 Chemotherapeutics 
According to the 2015 report Cancer Statistics, breast cancer is identified as one of the 
three most commonly diagnosed cancers in women, estimated to be as high as 29% of all new 
cancers diagnosed in women [1]. There are many chemotherapy drugs used for breast cancer 
treatment, including alkylating agents (such as cyclophosphamide), anthracyclines (such as 
epirubicin), antimetabolites (such as methotrexate), anti-mitotics (such as vinorelbine), and 
taxanes (such as paclitaxel), to name a few. Although cyclophosphamide is used to promptly 
control cancers, its rapid replacement with less toxic drugs is highly recommended as once it is 
in use it causes severe, life-threatening, adverse effects, such as permanent infertility and acute 
myeloid leukemia [2, 3]. Other chemotherapy drugs suffer from yielding comparable severe side 
effects. For example, the antineoplastic agent epirubicin may increase the risk of developing 
leukemia [4] or left ventricular dysfunction [5]. While vinorelbine, a semi-synthetic vinca 
alkaloid, is mostly employed as salvage therapy because it has more severe side effects than the 
standard lines of therapy [6].  
Compared with the above mentioned drugs, paclitaxel has many advantages. First, 
obtained from the pacific yew trees [7], it is environmentally safe and renewable. Second, as an 
antimicrotubule agent, it has been proven to be highly effective against breast, ovarian, head, and 
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neck cancers [8-10]. Most importantly, paclitaxel has a rare feature as a chemotherapeutic, which 
is effective for both reducing tumor size and terminating cancer cells. The primary mechanism 
related to the antitumor action of paclitaxel is that it promotes microtubule assembly, and 
induces the formation of nonfunctioning microtubules to prevent the formation and function of 
normal mitotic spindles, resulting in inhibition of cellular division [10]. Paclitaxel is extremely 
protein bound (88-98%) [11] and highly lipophilic [12]. However, for paclitaxel to be 
administrated intravenously an aqueous solution composed by Cremophor EL and ethanol is 
required, which can cause side effects, such as nephrotoxicity, hypersensitivity, and 
neurotoxicity [13, 14]. Moreover, due to paclitaxel’s undesired nature of hydrophobicity and fast 
plasma clearance when administered by infusion, its application is limited in oncology [15].  
 
2.2 Drug Delivery Systems 
Drug delivery systems are developed to optimize the therapeutic properties of drugs and 
improve their safety and efficacy. They aim to [16]: (1) reduce the frequency of dosing to 
improve patient compliance, (2) enhance the bioavailability of the drug to maximize its 
utilization, and (3) prevent the drug’s adverse side effects. So far, polymeric drug delivery 
systems have been proven effective when it comes to sustaining drug release and maintaining 
drug concentrations within therapeutic levels [17]. In general, biodegradable polymers are more 
commonly used than non-degradable polymers for drug delivery because of no necessity to 
recover the polymer after drug release. The drug’s release rate can be determined by the drug’s 
diffusion behavior and/or the degradation mechanism of the polymer system [18]. The following 
drug delivery systems have been studied extensively: micro/nanoparticles, hydrogels, and 
implants. 
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2.2.1 Micro/nanoparticles 
Generally speaking, this type of drug carrier aims to entrap, encapsulate, or attach the 
drug to a particle size of polymer matrix, and release the drug by diffusion and/or polymer 
erosion once it comes in contact with aqueous body fluids. Nanoparticles can be prepared 
through two major methods [19]: (1) dispersion of the polymer particles formed by 
emulsification, coacervation, or supercritical fluid technology; and (2) polymerization of 
monomers. Microparticles can be achieved through the above mentioned methods by adjusting 
the process parameters. Early work by Fonseca et al. focused on the development of paclitaxel-
loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles, which demonstrated a strong 
enhancement on anti-tumoral efficacy in comparison to the free drug Taxol [20]. Natural 
biodegradable polymers, such as chitin, can also be used to process into micro particles for 
localized delivery of paclitaxel in solid tumors, as reported by Nsereko and Amiji [21]. Although 
micro/nanoparticles help increase the stability of drugs and possess useful control release 
properties, the challenges of burst release and harmful chemical usage during fabrication still 
remain [19, 22]. 
 
2.2.2 Hydrogels 
Hydrogel based systems have also attracted increasing interest over the past two decades. 
The drug release is controlled by the hydrogel’s swelling property, as well as its stimuli-
responsive structure changes [23]. Lin et al. developed a novel thermo-sensitive paclitaxel-
nanocrystals (NCs)-Gel (Pluronic®F127) system, which were characterized by high drug-
loading and extended drug retention inside the tumor, due to its sustained, stable drug release 
[24]. In the work by Shim et al. [25], a PTX-loaded pH/T-sensitive block copolymer (OSM–
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PCLA–PEG–PCLA–OSM) solution showed the sustained release profile of paclitaxel for one 
month without burst release.  However, the inherent difficulties in stabilization of emulsions and 
satisfactory drug loading existed in hydrogels based systems [26-28].  
 
2.2.3 Implants 
Polymer implants can be fabricated to various shapes and sizes by biodegradable 
polymers [18], such as pellets, tablets, films, foams, and rods. The implantation methods include 
subcutaneously insertion and surgical placement [29]. This system is useful and effective for 
drugs with poor water solubility and short half-lives. A successful, commercial, polymer-based 
implant, Norplant, has been marketed in the United States since 1991, and has proven to be an 
effective approach for contraception [29]. By implanting the levonorgestrel-contained tubes in 
the upper arm, the Norplant system can successfully provide a therapeutical level of 
levonorgestrel for as long as 5 years. Ong et al. completed a more recent study [15]. They 
presented potential implants for post-surgical chemotherapy against malignant glioma, a 
paclitaxel-loaded, PLGA micro-porous foam fabricated by supercritical CO2 gas foaming. An in 
vitro evaluation showed the foam was able to provide a sustained paclitaxel release with 
minimum burst release.  Another group of scholars found hybrid films from blends of Chitosan 
and egg phosphatidylcholine (ePC) can provide a sustained release of paclitaxel over a 4-month 
period in an in vitro study [30].  
  
2.3  Biomaterials 
Materials (synthetic and natural) used in contact with biological systems are commonly 
called biomaterials [31]. Biomaterials have four major categories: polymers (the largest 
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category), metals, ceramics and natural materials. Polymers, including synthetic polymers and 
natural occurring biopolymers, are widely used in numerous medical devices, such as drug 
delivery systems, tissue engineering applications, dental, orthopedic, and so on [31, 32]. 
 
2.3.1 Synthetic polymers 
Synthetic polymers are synthesized through polymerization (addition and condensation) 
processes. Biodegradable and biocompatible synthetic polymers have been employed widely in 
drug delivery systems. The following synthetic polymers are commonly used for biomedical 
applications [31]: polycaprolactone (PCL), polyanhydrides, poly (glycolic acid) (PGA), poly 
(lactic acid) (PLA), and poly (lactic-co-glycolic acid) (PLGA).  
2.3.1.1 Polycaprolactone (PCL) 
PCL is a semi-crystalline biodegradable polymer. It has acceptable mechanical properties 
and a slow rate of hydrolysis, which makes it suitable for long-term (over 1 year) drug delivery 
carriers, orthopedic applications and stents. The use of PCL in drug delivery applications has 
been well established [31, 33]. However, because of its hydrophobic nature, semi-crystalline 
structure, and slow hydrolysis degradation in human body, its clinical application has been 
limited [34]. 
2.3.1.2 Polyanhydrides 
Polyanhydrides are well-known synthetic biodegradable polymers used mostly in drug 
delivery systems owing to their unique benefits. For instance, they are easily prepared from 
economical resources in one-step synthesis without a purification process. Moreover, with 
certain manipulation, polyanhydrides can release drugs at a predictable rate for weeks to months 
[35]. One polyanhydride wafer containing chemotherapeutics, Gliade, has been in clinical use for 
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brain tumor chemotherapy [36, 37]. However, polyanhydrides’ hydrolytic instability [31, 35] and 
high chemical reactivity [31] limit their use.  
2.3.1.3 Poly (glycolic acid) (PGA) and poly (lactic acid) (PLA) 
PGA and PLA are both linear aliphatic polyesters [31]. Both degrade in the human body 
by hydrolysis of their ester backbone to non-toxic compounds discharged metabolically. PGA is 
more hydrophilic, while PLA is more hydrophobic. PGA is a rigid thermoplastic material with 
high crystallinity, and can be fabricated by polycodensation or ring-opening polymerization, 
while PLA is a semi-crystalline solid that can be synthesized from low-cost natural raw materials, 
such as corn. In addition, they are both non-immunogenic and biodegradable polymers with 
acceptable mechanical properties. Hence, PGA and PLA have become the most widely studied 
polymers in medical applications and tissue engineering [38, 39], e.g. absorbable sutures [40, 41]. 
However, two major challenges exist with the use of PGA. One is PGA’s high sensitivity to 
hydrolytic degradation requires devising precise processing [40]. The other challenge is due to a 
lack of functional diversity in the backbone, where the modulation of its degradation rate and 
chemical properties are inhibited [41]. As for PLA, hydrophobicity and acid degradation 
products are the main weaknesses.  
2.3.1.4 Poly (lactic-co-glycolic acid) (PLGA) 
Poly (lactic-co-glycolic acid) (PLGA) is a synthetic copolymer composed by poly lactic 
acid (PLA) and poly glycolic acid (PGA) [42]. Among the various polymers used in drug 
delivery systems, PLGA has gained a lot of popularity due to its biodegradability, 
biocompatibility, ease of processing and excellent mechanical properties [43]. This polymer 
degrades to non-toxic, water-soluble products—lactic acid and glycolic acid—through hydrolysis 
in the human body fluid environment. Owning to its excellent biocompatibility, biodegradability, 
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and compatibility with drugs, PLGA has become one of the FDA-approved, biodegradable 
polymers [44]. According to the review conducted by Makadia and Siege [42], PLGA possesses 
great mechanical ability allowing it be processed into almost any shape and size. The review also 
pointed out it can be fabricated to micro/nanoparticles [13, 20, 45, 46] by solvent evaporation, 
phase separation, and spray drying, or processed into implants by solvent-casting, compression 
molding, and extrusion. PLGA foams [15], films [47], electrospun fibers [48], and hydrogels [25] 
also have been successfully produced for drug delivery applications and tissue engineering. 
Similar to PGA and PLA, PLGA still has drawbacks which hinder its use as a drug 
carrier. One of the most common problems is the accumulation of acidic degradation products 
during the degradation of matrix systems, which may trigger a nonbacterial inflammation at the 
implant site [49, 50]. Also, because PLGA degrades through bulk erosion, the required drug 
release profile is difficult to obtain.  
 
2.3.2 Natural polymers 
Natural polymers (biopolymers) refer to naturally occurring polymers, such as polymers 
derived from animal or plant sources [31]. These types of polymers have been under extensive 
investigation for use in drug delivery systems due to their biodegradability, biocompatibility, and 
renewable nature. Two major representative degradable biopolymers, collagen and 
polysaccharides (e.g. chitosan), are discussed. 
2.3.2.1 Collagen 
Collagen is derived from animal sources (e.g., bovine, porcine, etc.) and possesses an 
excellent biocompatibility because it widely exists in bones, muscles, skin and tendons [51]. It 
can be used for a variety of medical devices due to its versatile functionality and absorption 
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features [52], such as artificial skins [53], orthopedic applications [54], soft tissue augmentation 
[55], dental applications [56] and drug delivery systems [57]. In an early study of collagen-based 
drug delivery systems for protein drugs (e.g. human serum albumin), Maeda et al. [58] suggested 
that after a relatively small initial burst release, human serum albumin was released from 
collagen minipellets mainly by diffusion. Although collagen has outstanding functionality and 
mechanical properties as a potential biomaterial, its development in clinical use is inhibited due 
to the imperative request for methodologies to purify and sterilize it [31]. 
2.3.2.2 Chitosan 
Chitosan is one of the most abundant, natural polymers in the world. Its characteristic 
biocompatibility and biodegradability makes it very attractive and practical for its use in 
biomedical applications [38, 50, 59-69], including drug delivery systems, wound dressings, and 
artificial tissue/organ implants [62, 70]. Chitosan does not induce an immune response in the 
human body. It decomposes into harmless products (amino sugars) by hydrolysis and enzymatic 
degradation by lysozyme [71]. Bhattarai et al. investigated the newest developments in chitosan 
hydrogel preparation and concluded chitosan hydrogel can be utilized in the context of localized 
drug delivery and controlled release to its target [72].  
Distinguished from many other natural polymers, chitosan is a cationic polysaccharide 
[71] composed of randomly distributed β-(1-4)-linked D-glucosamine and N-acetyl-D-
glucosamine units [72, 73]. Hence, adding chitosan to a PLGA implant may provide some 
advantages in comparison to using PLGA alone, such as neutralizing the acidity at the implant 
site.  In fact, the biomaterial applications involving composites of PLGA and chitosan have been 
reported previously. Chakravarthi and Robinson confirmed chitosan-PLGA particles are able to 
enhance cellular association and cytotoxicity of paclitaxel [74].  Other similar studies on the use 
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of chitosan with biodegradable polymers have been conducted as well. Zhu et al. reported a 
composite scaffold made from chitosan microspheres and synthetic poly (L-lactic) (PLLA) is 
applicable for tissue engineering because of its adjustable degradation property [50]. A scaffold 
composed by Polyglycolide (PGA) and chitosan also has been proposed [38], and the study 
showed the PGA-chitosan (containing 30%w/w chitosan) hybrid matrix is a promising 
biomaterial for a variety of artificial tissue systems, due to its high porosity and good mechanical 
properties. However, blending Chitosan with PLGA to make a bulk implant for delivery of 
paclitaxel has not been reported previously.  
Most of previous studies employed emulsification, solvent evaporation, or chemical 
conjugation to incorporate into or onto PLGA [74]. However, the substance produced by these 
methods is unsuitable for injection molding. 
 
2.4 Manufacturing Processes for Drug Delivery Systems 
Polymeric drug delivery systems can be processed and fabricated in various forms and 
sizes by certain manufacturing methods. Most nano/micro particle sized drug delivery systems 
are prepared through emulsification or polymerization of monomers [19].  For those macroscopic 
millimeter size drug implants, solvent casting, compression molding, extrusion, or injection 
molding are primarily employed [42].  In addition, more techniques have been explored to 
manufacture drug delivery systems, such as cryomilling, a novel method to grind and blend 
materials under cryogenic condition [75].   
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2.4.1 Emulsification  
Emulsification is the most commonly used technique for fabrication of drug incorporated 
particles [19]. The process involves two or more liquids usually immiscible, e.g., water and oil. 
By dispersing one liquid in the other through stirring or sonicating, an emulsion can be achieved, 
such as oil-in-water emulsion or water-in-oil emulsion. To stabilize the emulsion, surfactants are 
often used while preparing and storing the emulsion. Mu and Feng [46] proposed a novel 
formulation containing vitamin E TPGS as an emulsifier or a component of the polymer matrix 
to fabricate paclitaxel loaded nanoparticles. Although this technique is effective, there still 
remain some drawbacks. For instance, emulsification requires precise control of processing 
parameters for consistency of the final product and efficiency of drug encapsulation. Moreover, 
the need for a large quantity of organic solvent makes the process unrealistic for industrial 
scalable production [19, 42] and the use of surfactants may cause side effects.  
 
2.4.2 Solvent casting 
In the solvent casting method, polymers and drugs are dissolved in a common solvent at 
ambient temperature, and then the solution is cast into a Teflon plate or glass dish [76]. After 
evaporation of the solvent, drug-loaded polymer films are obtained. This method is proven to 
achieve homogenous dispersion of drugs in polymer matrices [77]. However, Makadia and 
Siegel [42] argued that solvent casting is not ideal for industrial scale-up, due to the use of large 
amounts of organic solvents and the possibility of causing polymer denaturation.  
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2.4.3 Extrusion 
Extrusion is a continuous process to draw melted materials through a die to create objects 
of a fixed cross-sectional profile [31]. Polymers and drugs mixtures can be extruded into tubes or 
fibers. During the process, polymers and drugs mixtures are heated to a semi-liquid state in the 
chamber, and then pushed by the screw through the die [78]. The extrudate is cooled and 
solidified before trimming to expected lengths. Since this process requires heat treatment to melt 
the materials, it could lead to polymer and drug denaturation [42]. Hence, the melting point and 
thermal stability of drugs, along with the chemical interactions between the used polymers and 
drugs should be carefully evaluated before adopting this manufacturing method.  
 
2.4.4 Injection molding 
Injection molding has been employed widely for the production of biomedical devices in 
previous research studies [79-85]. This is a common manufacturing technique more appropriate 
for large-scale, industrial production [78] and available for making various shapes of implants 
[78, 86]. Briefly, the process melts the thermoplastic or thermoset materials, and injects them 
into a closed mold to obtain the desired shape and size. Wu et al. [83] proposed a "room-
temperature" injection molding combined with the particulate leaching method to fabricate three-
dimensional, porous scaffolds by using a "wet" composite of particulate/polymer/solvent in the 
process of injection molding to avoid the inconvenience of handling high viscosity substances 
and thermal degradation of polymers. They found the approach might be promising in tissue 
engineering and other application fields.  
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2.4.5 Cryomilling 
Cryomilling is a technique used to reduce the agglomeration of the substance by crushing 
it under cryogenic temperatures using a solenoid to move the grinding media back and forth 
inside the vial. This has become an effective technique to pulverize and blend substances, 
including polymers and metals [87, 88]. Several articles focus on using cryomilling to fabricate 
biodegradable scaffolds comprised of immiscible polymers to avoid undesirable chemical 
reactions, unstable morphologies, and unwanted polymer degradation caused by melt blending or 
the use of harmful solvents [88, 89]. Lim et al. used cryomilling to achieve micrometer-sized 
distribution of polycaprolactone (PCL) and tricalcium phosphate (TCP), and then processed them 
with compaction and melting to obtain composite scaffolds [89]. Their work demonstrated an 
easy access, polymer powder processing technique to overcome limitations on distribution and 
loading of biologically active molecules. In conclusion, to achieve a homogeneous blend 
consisting of highly viscous polymers (e.g., PLGA) and thermal sensitive materials (e.g. 
chitosan), cryomilling could be an appropriate manufacturing method to not only secures the 
integrity of the materials, but also to enhance the degree of dispersion.  
 
2.5 Summary of Literature 
This literature review aims to demonstrate the need for a more effective drug delivery 
system for hydrophobic chemotherapeutics. (1) A more appropriate drug delivery system is 
needed for paclitaxel, since the commercial method has severe side effects and the current novel 
methods still have challenges to overcome. (2) The proposed PLGA rod-shaped polymer system 
can be produced and implanted easily into the human body via insertion, and blending chitosan 
in the PLGA implant could alter the degradation rate to achieve prolonged drug release. (3) No 
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previous study was presented in the literature for fabrication of chitosan-blended PLGA implant 
for delivery of anti-tumor agents through cryomilling and injection molding. 
 
2.6 Thesis Organization 
Chapter 1 presents the general introduction of this work. Chapter 2 provides a literature 
review of the state of delivery systems for paclitaxel and possible strategies for improving the 
drug’s release by employing polymers as delivery mechanisms. This review demonstrates the 
need for a more effective drug delivery method for chemotherapeutics (i.e., paclitaxel) to solve 
the problems of low efficiency of the systemic delivery of high doses of toxic drugs for localized 
tumors. To fill this void, Chapter 3 presents original work in the format of paper for peer review 
publication titled an implantable sustained-release chemotherapy delivery system for the 
treatment of breast cancer. Chapter 4 of this thesis provides general conclusions and an outline 
for future research directions. 
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CHAPTER 3                                                                                                                                
AN IMPLANTABLE SUSTAINED-RELEASE CHEMOTHERAPY DELIVERY 
SYSTEM FOR THE TREATMENT OF BREAST CANCER 
Manuscript to be submitted to the Journal of Medical Devices 
Yunqing Chen and Iris V. Rivero 
 
Abstract 
 
A Poly (Lactic-co-Glycolic Acid) (PLGA) and chitosan based biodegradable implant was 
designed for the sustained release of the hydrophobic chemotherapeutic Paclitaxel (PTX) 
intramuscularly or subcutaneously. PLGA-PTX blends were fabricated via solvent method then 
mixed with chitosan in a 30:70 mass ratio by cryomilling. The powder mixture was then molded 
to rods by injection molding. The content uniformity, morphology, and thermal properties were 
investigated by x-ray diffraction, scanning electron microscope and differential scanning 
calorimetry, respectively. The drug loading content (LC), encapsulation efficiency (EE) and the 
drug release were measured by ultraviolet-visible spectrophotometry (UV-Vis).  In vitro study 
revealed that the chitosan blended PTX-PLGA implant possesses a prolonged drug release. 
Chitosan showed a potential to regulate and control PLGA implant degradation. 
Key words: Poly (Lactic-co-Glycolic Acid) (PLGA), chitosan, breast cancer, drug delivery, 
cryomilling 
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3.1    Introduction 
Since chemotherapeutics usually cause a risk of local toxicity in the gastrointestinal track 
[1], they are commonly administered intravenously instead of orally. In spite of the effectiveness 
of traditional infusion-based chemotherapy, there are problems associated with the systemic 
delivery of high doses of toxic drugs that fail to provide a desired drug concentration to localized 
tumors [2]. For instance, the solubilizer, Cremophor EL, use to form the clinical liquid solution 
for chemotherapeutic Paclitaxel is found to cause severe side effects [3, 4]. Thus, drug delivery 
devices have been explored extensively for the purpose of maximization of the anticancer agent 
effects and minimization of the side effects on healthy cells and tissues [4-7]. 
Biodegradable polymer drug delivery systems are commonly used since there is no 
necessity to recover the polymer after drug release, and because they have been proven to be 
effective for sustained drug release while maintaining drug concentrations within therapeutic 
levels [8]. Moreover, local administration of chemotherapeutics via implantation of a drug-
incorporated polymer device could be a practical way to reduce systemic exposure, increase the 
dosage of drugs at specific area, [9] and optimize the drugs therapeutic effects [9]. An example 
of a commercially successful polymer-based drug delivery system is Norplant, which has been 
marketed in the United States since 1991, and has proven to be an effective approach for 
contraception [10]. Several forms of drug delivery systems have been made with biodegradable 
polymers, i.e., micro/nano particles, micelles, hydrogels, and implantable solid dispersions, 
wafers, films, and rods [8, 11]. Unfortunately, each of these drug delivery systems presents 
unique shortcomings. For instance, although micro/nano particles have proven to improve 
treatment efficacy while reducing toxicity, the challenges of low drug loading and high burst 
release still remain [12, 13]. While with micelles and hydrogels, there are concerns over their use 
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due to residuals of potentially toxic crosslinking agents [14] or solvents used for their 
fabrication, and more relevant due to the technical obstacle of colloid stabilization [6, 14, 15]. To 
circumvent these issues, we present an injectable rod-shaped polymeric implant for the delivery 
of chemotherapy drugs. 
Paclitaxel (PTX) is a highly toxic chemotherapeutic [16]. It is widely used as an 
antimicrotubule agent for treating a variety of cancers, including breast, ovarian, head, and neck 
[17]. However, due to its undesired nature of hydrophobicity and fast plasma clearance when 
administered by infusion, its application is limited in oncology [18]. Various studies have 
focused on employing polymers to act as drug vehicles for PTX, such as Poly (Lactic-co-
Glycolic Acid) (PLGA) [19], Polycaprolactone (PCL) [20] and Poly (lactic acid) (PLA) [21]. 
Among the available biomaterials, PLGA is the most popular biodegradable polymer, due to its 
favorable degradation characteristics and immense potential for sustained drug delivery [5]. 
PLGA is an FDA-approved biocompatible and biodegradable synthetic polymer. Various 
studies reporting on the use of PLGA as carrier for paclitaxel have been published where the use 
of PLGA nanoparticles as effective drug carriers in cancer therapy is explored [3, 18, 22-24]. 
Additionally, other studies emphasizing the use of PLGA as drug delivery implants indicated that 
besides nanoparticles, PTX-loaded PLGA foams [18], compressed microsphere sheets [25], and 
microfiber discs [26] can also provide a sustained PTX release with minimum initial burst. 
However, limited work has been reported on the use of PLGA as injectable solid implants for 
delivery of PTX, which could be easily inserted and provide a sustained drug release at a tumor 
site. Therefore this study, introduces the design of injectable PTX solid implants containing the 
biodegradable cationic polymer, chitosan [27], to reduce the risk of local acidosis resulting from 
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the accumulation of PLGA hydrolysis products, lactic acid and glycolic acid, at the implantation 
location [27]. 
Chitosan is a naturally-occurring polysaccharide [28] composed of randomly distributed 
β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine units [16, 28]. It has been used in 
tissue engineering and pharmaceutical fields due to its versatile biological characteristics [27]. 
However, because chitosan is non-soluble in organic solvents or water [29], the incorporation of 
PTX cannot be achieved by the solvent method. Meanwhile, to avoid the use of high-heat 
methods (grinding, melting, etc.), which could result in decomposition of the biopolymer, 
cryomilling [30-32] was employed to homogeneously blend chitosan with PTX and PLGA [30-
32]. 
In this work, a fabrication process without using solvent to integrate chitosan with PLGA 
has been developed and investigated. The influence of chitosan on the PTX release of PTX-
loaded PLGA rod-shaped implants, and the resulting pH levels in the local medium was 
investigated through in vitro release studies. Overall fabrication of implants included a solvent 
method followed by cryomilling and injection molding. The integrity of the blends was 
ascertained via X-ray diffraction (XRD). The miscibility between the drug and excipients was 
evaluated via Differential Scanning Calorimeter (DSC). In vitro release studies were performed 
in a phosphate buffer solution pH 7.4. 
 
3.2    Materials and Methods 
PLGA 50:50 (PDLG 5002) was purchased from Purac Biomaterials (Gorinchem, 
Netherlands). Paclitaxel was purchased from TSZCHEM (Framingham, Massachusetts, USA). 
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Chitosan (medium molecular weight), phosphate buffered saline (PBS) and methylene chloride 
(DCM) were acquired from Sigma-Aldrich Co. LLC (Missouri, United States). 
 
3.2.1 Preparation of polymer implants 
3.2.1.1 Polymer implants formulations 
Table 3.1 lists the detailed formulations used in this work. In this study, 10%w/w of PTX 
drug loading was used [18]. In order to investigate the effect of 30% w/w chitosan (CHI) on 10% 
w/w PTX drug loaded PLGA implants drug release, PLGA-PTX implants, and PLGA-PTX-CHI 
implants were compared [33] in in vitro release studies. Meanwhile, the polymer erosion of 
different formulations was monitored by mass loss. 
Table 3.1 Polymer implant formulations 
Drug Composition Feed Weight Ratio 
 
 PLGA PTX Chitosan 
PLGA 100 0 0 
PLGA-PTX 90 10 0 
PLGA-CHI 70 0 30 
PLGA-PTX-CHI 60 10 30 
 
3.2.1.2 Fabrication protocol for polymer implants 
The fabrication protocol of the implants consists of the following three steps: (1) 
incorporation of PTX into the PLGA polymer matrix by solvent method, (2) blending of chitosan 
and PTX-loaded PLGA by cryomilling, and (3) molding into rod-shaped implants via a lab-scale 
injection molding device. 
Specifically, first PLGA and PTX were dissolved in the organic solvent methylene 
chloride (DCM), and magnetic stirred at room temperature for 1 hour. DCM was evaporated in a 
fume hood for 12 hours followed by drying at 25°C for 6 hours in a vacuum oven. The solid 
  
35 
 
 
 
dispersion was collected then. Chitosan was introduced to the PLGA PTX-loaded PLGA 
dispersion via cryomilling (SPEX SamplePrep 6770 Freezer/Mill, United States). The 
cryomilling protocol is depicted as follows: pre-cool material for 10 minutes, grinding for 6 
minutes at a rate of 15 cycles per second (CPS) 3 times, cool down for 2 minutes between each 
operation.  
Implants (1mm of diameter × 15mm of length) were finally molded in a lab-scale 
injection molding device. Mold was pre-heated to about 70°C [5]. Then, 0.8 g of the prepared 
powder mixture was charged into the mold. By applying pressure onto the guide rod (piston), the 
melt polymer mixture was injected through a 5 mm diameter nozzle into the mold cavity and 
formed into rod-shaped implants. After cooling down the mold, the implants were removed from 
the mold and stored in a freezer to preserve the integrity of PLGA and PTX. 
 
3.2.2 Polymer implants characterization. 
The integrity of the drug-polymers blends was ascertained via x-ray diffraction. 
Meanwhile, x-ray diffraction was able to investigate the crystallinity of blended polymers, which 
has direct influence on the mechanical strength, capacity to undergo hydrolysis, and 
subsequently, biodegradation rate. The x-ray diffraction (XRD) studies were conducted on each 
formulation sample prior to in vitro release studies. Samples were mounted into glass slides and 
scanned over a 2-theta range of 1-60° at a rate of 5°/min. All XRD patterns were obtained using 
an X-ray diffractometer (MiniFlex 600, Rigaku, Japan) equipped with Cu K-alpha radiation 
source (40kV, 15mA). The homogeneity of PLGA-PTX-CHI rod was evaluated through Energy 
Dispersive X-ray Spectroscopy (EDS). Since PTX and chitosan both have nitrogen element, EDS 
experiment was conducted to compare nitrogen content in different section of a rod. 
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The morphology of the surface and cross-section of the implants were observed by 
scanning electron microscope (SEM) (JCM-6000 NeoScope Benchtop SEM, JEOL Ltd., Japan). 
To investigate the miscibility between the drug and excipients, the glass transition 
temperatures (Tg) of implants were determined by differential scanning calorimetry (DSC 204 
F1 Phoenix, NETZSCH, Germany). Additionally, the implants underwent in vitro release studies 
in different periods of time were also examined by DSC to capture changes in glass transition 
temperatures. All specimens were weighed to approximately 5-10 mg and analyzed by using a 
heat/cool/heat mode to eliminate their thermal history. A blank aluminum pan (pierced, 40mg) 
was applied as reference in all analyses. Each run consisted of initially heating up the samples to 
250.0°C at a heating rate of 20.0 K/min, followed by a second heating cycle to 250.0°C again at 
the same heating rate after cooling down to -40.0°C at 20.0 K/min [34]. The Tg of the polymeric 
rods were analyzed from the second heating cycle. 
 
3.2.3 Drug Loading Content (LC) and Drug Encapsulation Efficiency (EE). 
In this study, an established quantitative analysis of PTX [35] through UV-Vis 
(LAMBDA 750 UV/Vis/NIR Spectrophotometer, PerkinElmer, U.S.) was employed. In this 
method, methanol and PBS (pH 7.4) in a ratio of 30:70 [35] was used as solvent, and PTX 
absorbance was measured at λmax (230nm) against blank solvent. The standard calibration curve 
in the concentration range of 1-20µg/ml was determined as follow:  
Y = 0.0348X+0.0036 (R2= 0.998)                     (1) 
where Y is the absorbency of PTX at 230nm, X is the concentration of PTX and R2 is the 
regression coefficient. The percentage recovery of PTX was found to be 98.30% to 102.55%. 
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The drug loading content (LC) and the drug encapsulation efficiency (EE) were 
determined in triplicate using UV-Vis assay described below. Accurately known weights (~5mg) 
of rods were dissolved in 2ml DCM first, and then were added 2ml methanol to the residue after 
DCM had evaporated. The solution was centrifuged at 6500rpm for 15min after being agitated 
overnight, then the supernatant was extracted. PBS and methanol was added into the supernatant 
to adjust the finial solvent made up with 30:70 methanol: PBS. The corresponding concentration 
was determined by the equation (1). The drug loading content (LC) and the drug encapsulation 
efficiency (EE) were obtained through the following formula [36]:  
LC% =  × 100                                   (2) 
EE% =  × 100,                                     (3)               
where  is the mass of PTX loaded in implants, and  is the mass of implants,  
is the mass of PTX added initially during the fabrication.   
 
3.2.4 In vitro Release Studies 
3.2.4.1 PTX Release from Implants. 
The in vitro PTX release studies for the implants PLGA-PTX and PLGA-PTX-CHI were 
carried out in 15mL of PBS (pH 7.4) in triplicate. All tubes were capped, sealed, and placed in an 
incubator at 37°C at 60 rpm [37]. Because human body is a huge buffer system, the study was 
using PBS (pH 7.4) to simulate human body environment. Each day 5ml of buffer was removed 
and replaced with same amount fresh PBS to maintain sink conditions throughout release. 
Meanwhile, PTX in the removed release medium was measured to determine the total release 
amount of PTX. The steps were described below: first, to extract PTX by adding 2ml DCM and 
allowing mass transfer for one day [18]; then, after DCM had evaporated, methanol was added to 
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the extracted PTX followed by PBS to adjust the finial solvent concentration to 30:70 methanol: 
PBS. The corresponding concentration was calculated by the equation (1). To correct the 
detected data, the extraction efficiency had to be analyzed [18, 38]. Hence, a known amount of 
PTX was dissolved into PBS solution and was later extracted using the same procedure. The 
extraction efficiency was found to be 76.4%, which indicated that after the extraction procedure, 
the obtained solution only contained 76.4% of PTX in the original solution.    
3.2.4.2 Mass Loss of Implants. 
Previous studies have shown that the drug release kinetics of drug delivery systems made 
from biodegradable polymers are controlled by diffusion and/or erosion [39]. Polymer erosion 
refers to depletion and physical changes of polymer which caused by degradation, swelling, 
dissolution and diffusion of oligomers and monomers [40].  Hence, to investigate the impact of 
the polymer erosion on drug release, mass loss of the implants with respect to time was taken as 
a measure of erosion in in vitro release studies. Individual implants were weighed initially as 
minitial. At fixed time intervals of two days until day 30 was reached, specimens (n=3) were taken 
out from the tube and washed with distilled water, then dried by vacuum oven at 20°C for 24 
hours and weighted as mXDD. The mass loss was defined as follows [41, 42]: 
%Mass loss = (minitial − mXDD)/minitial × 100               (4) 
where, mXDD is the weight of specimen after X Days of Degradation, and minitial is the initial 
weight of the dry implants before in vitro release studies. 
 
3.2.5 pH change in release medium 
To investigate the pH change in the medium during in vitro release, triplicate samples of 
the implants from each drug formulation were placed individually in 15ml of PBS (pH 7.4) in an 
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incubator with the same condition of in vitro release studies (37°C and at 60 rpm, refreshing 5ml 
PBS every day). Meanwhile, to eliminate the influence of refreshing PBS, pH change studies 
without refreshing PBS were conducted as well to investigate the effect of chitosan on release 
medium pH change. At various time intervals, pH measurements were performed with the 
Sartorius Basic Meter PB-11.  
 
3.3    Statistical Analysis 
The drug loading content (LC), encapsulation efficiency (EE) of PLGA-PTX and PLGA-
PTX-CHI implants were statistically analyzed by Student’s t-test. Results of the mass loss in in 
vitro drug release studies, and pH change studies are presented as mean ± standard deviation 
(S.D.), and analyzed by one-way analysis of variance (ANOVA) with Tukey’s post hoc analysis. 
Statistical difference was accepted when p≤0.05 (95% confidence interval). 
 
3.4    Results and Discussion 
3.4.1 Polymer implants characterization 
The XRD patterns of pure chitosan, pure PTX and the four formulations of implants are 
shown in Figure 3.1 arranged in descending order by the intensity of the peak at 2-theta ≈ 20°. 
As a crystalline polymer, pure chitosan exhibits two clear characteristic peaks at 2-theta - 10.4° 
and 19.6° in the diffractogram, which is in accordance with the results found by Kumar and Koh 
[38]. Unlike chitosan’s high intensity narrower peaks, a broader peak in the 18-25° is shown in 
the spectra for the implants PLGA-CHI and PLGA-PTX-CHI, which may have been contributed 
by the high percentage of the amorphous polymer PLGA. The phenomenon of broadened peak, 
that is the decreased intensity was due to the reduction in crystallite size. Implants that did not 
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contain chitosan, PLGA and PLGA-PTX implants, displayed a broad peak in the diffractogram 
due to the large proportion of amorphous polymer PLGA. Also, no characteristic crystalline 
peaks were observed for PTX in the spectra suggesting that PTX was amorphous in the implants.  
EDS analysis indicated that the concentrations of element nitrogen at different locations 
of PLGA-PTX-CHI rod are almost the same (1.98 ± 0.13%). Although element nitrogen is 
present on both PTX and CHI, EDS analysis of PLGA-PTX implants did not detect nitrogen, 
which probably due to the extremely low concentration of nitrogen in PLGA-PTX implants (the 
theoretical value: 0.16%) which is beyond the sensitivity range of the EDS. The results showed 
in Figure 3.2 confirmed that a homogenous composition throughout the rod.  
The cross section and surface morphologies of each formulation implant before and after 
in vitro were examined by SEM and presented in Figure 3.3-3.6, respectively. For the PLGA and 
PLGA-PTX implants, a coarse surface and an interconnected porosity was observed, which 
could be attributed to the bulk erosion of the PLGA matrix. But, fewer irregular cracks existed 
on the PLGA-PTX implants than in the PLGA implants, which might be attributed to the 
hydrophobic PTX being dispersed in the PLGA matrix, and assumed to keep the implants from 
collapsing and disintegrating. For the PLGA-CHI and PLGA-PTX-CHI implants, although 
erosion occurred on the surface of the implants, the cross section images implied that there was 
no sign of water penetration in the interior of the implants after 30 days. This phenomenon might 
be due to the process of PLGA hydrolysis being suppressed to some degree as a result of 
chitosan protonation, which is the adsorption of hydrogen ions, leading to an alkaline medium. 
The glass transition temperatures (Tg) of as-manufactured samples and in vitro tested 
samples were determined by DSC, results for four formulations implants are presented in Figure 
3.7-3.10. It appears that the Tg of PLGA and PLGA-PTX sample implants, gradually decreased 
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with longer in vitro duration. This result corresponds to the PLGA erosion mechanism, bulk 
erosion, which leads to Tg decrease as PLGA degradation proceeds [44]. Specifically, during the 
degradation process, the polymer chains split into random segments first, which leads to decrease 
of the molecular weight of PLGA without an appreciable mass loss; then due to the formation of 
soluble monomers and oligomers, the mass of PLGA drops rapidly. However, the DSC 
thermograms for the PLGA-PTX-CHI and PLGA-CHI implants (before and after 30 days of in 
vitro release studies) did not exhibit such change in Tg as the PLGA and PLGA-PTX implants, 
even though morphological changes were observed on the surface of the implants.  
Considering the observations from SEM, it appears that the determined Tgs of PLGA-
CHI and PLGA-PTX-CHI implants represented mostly the inner part of the implants, which may 
have not encountered any degradation or erosion. This observation demonstrates that the 
degradation mechanism of chitosan incorporated implants may be in line with surface erosion 
instead of bulk erosion. 
According to a prior study conducted by Averineni et al. [3], the characteristic 
endothermic peak of pure PTX is at around 220°C on the DSC thermogram. However, from DSC 
results derived for the PLGA-PTX and PLGA-PTX-CHI implants no melting phenomenon was 
observed. Such behavior may be due to the conversion of PTX from a crystalline to an 
amorphous state and/or it being dissolved in the polymer matrix. The reason that the DSC curve 
does not detect the Tg of chitosan may be associated with the thermal decomposition that occurs 
during the glass transition of chitosan due its semi-rigid molecular properties. 
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Figure 3.1 XRD diagram for pure CHI, pure PTX and the four formulations of implants 
 
 
Figure 3.2 EDS analyses of PLGA-PTX-CHI implant at different locations as labelled by the 
numbers
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Figure 3.3 SEM images of cross section morphologies of (PLGA 1) PLGA implant 
specimen before degradation experiment, (PLGA 2) PLGA implant specimen after 14 days 
degradation, (PLGA 3) PLGA implant specimen after 30 days degradation, (PLGA-CHI 1) PLGA-
CHI implant specimen before degradation experiment, (PLGA-CHI 2) PLGA-CHI implant 
specimen after 14 days degradation, (PLGA-CHI 3) PLGA-CHI implant specimen after 30 days 
degradation     
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Figure 3.4 SEM images of cross section morphologies of (PLGA-PTX 1) PLGA-PTX 
implant specimen before degradation experiment, (PLGA-PTX 2) PLGA-PTX implant 
specimen after 14 days degradation, (PLGA-PTX 3) PLGA-PTX implant specimen 
after 30 days degradation, (PLGA-PTX-CHI 1) PLGA-PTX-CHI implant specimen 
before degradation experiment, (PLGA-PTX-CHI 2) PLGA-PTX-CHI implant specimen 
after 14 days degradation, (PLGA-PTX-CHI 3) PLGA-PTX-CHI implant specimen after 
30 days degradation 
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Figure 3.5 SEM images of surface morphologies of (PLGA 4) PLGA implant specimen 
before degradation experiment, (PLGA 5) PLGA implant specimen after 14 days 
degradation, (PLGA 6) PLGA implant specimen after 24 days degradation, (PLGA 7) 
PLGA implant specimen after 30 days degradation, (PLGA-CHI 4) PLGA-CHI implant 
specimen before degradation experiment, (PLGA-CHI 5) PLGA-CHI implant specimen 
after 14 days degradation, (PLGA-CHI 6) PLGA-CHI implant specimen after 24 days 
degradation, (PLGA-CHI 7) PLGA-CHI implant specimen after 30 days degradation 
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Figure 3.6 SEM images of surface morphologies of (PLGA-PTX 4) PLGA-PTX implant 
specimen before degradation experiment, (PLGA-PTX 5) PLGA-PTX implant specimen 
after 14 days degradation, (PLGA-PTX 6) PLGA-PTX implant specimen after 24 days 
degradation, (PLGA-PTX 7) PLGA-PTX implant specimen after 30 days degradation, 
(PLGA-PTX-CHI 4) PLGA-PTX-CHI implant specimen before degradation experiment, 
(PLGA-PTX-CHI 5) PLGA-PTX-CHI implant specimen after 14 days degradation, 
(PLGA-PTX-CHI 6) PLGA-PTX-CHI implant specimen after 24 days degradation, 
(PLGA-PTX-CHI 7) PLGA-PTX-CHI implant specimen after 30 days degradation 
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Figure 3.7 DSC thermogram of PLGA implant specimen before degradation experiment, after 
8 days degradation, after 16 days degradation, after 24 days degradation and after 30 days 
degradation 
 
 
 
Figure 3.8 DSC thermogram of PLGA-PTX implant specimen before degradation experiment, 
after 8 days degradation, after 16 days degradation and after 24 days degradation
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Figure 3.9 DSC thermogram of PLGA-CHI implant specimen before degradation experiment, 
after 8 days degradation, after 16 days degradation, after 24 days degradation and after 30 days 
degradation 
 
 
 
Figure 3.10 DSC thermogram of PLGA-PTX-CHI implant specimen before degradation 
experiment, after 8 days degradation, after 16 days degradation, after 24 days degradation and 
after 30 days degradation 
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3.4.2 Drug Loading Content (LC) and Drug Encapsulation Efficiency (EE) 
Table 3.2 summarized the drug loading content (LC) and drug encapsulation efficiency 
(EE) for PLGA-PTX and PLGA-PTX-CHI implants. No significant differences (p>0.05) were 
observed between two formulations. Drug loading content for PLGA-PTX and PLGA-PTX-CHI 
implants were 9.81 ± 0.05% and 9.73 ± 0.20% (w/w), respectively, which were close to the feed 
weight ratio (Table 3.1) of PTX to polymers (10%). During fabrication, some of drugs and 
polymers could remained in the vial of cryomilling and injection molding mold, giving rise to an 
encapsulation efficiency of ~ 80%. 
Table 3.2 Drug loading content (LC) and drug encapsulation efficiency (EE) of PLGA-PTX and 
PLGA-PTX-CHI implants 
Drug Composition LC (%) EE(wt%) 
PLGA-PTX 9.81 ± 0.05 86.08 ± 0.40 
PLGA-PTX-CHI 9.73 ± 0.20 84.85 ± 0.63 
The data are expressed as mean± S.D. (n=3) 
Student’s t-test, p > 0.05 
 
3.4.3 In Vitro Release Studies 
3.4.3.1 PTX Release from Implant. 
The in vitro release curves of PTX from PLGA-PTX and PLGA-PTX-CHI implants were 
shown in Figure 3.11. The release pattern of PTX from PLGA-PTX implants demonstrated a 
three-phase release profile: a very slow release during first 7 days, followed by a rapid release 
from day 8 to day 34, then another sustained and slow release appeared in the last 4 days. 
However, PLGA-PTX-CHI implants began to release PTX after 16 days in a slow and steady 
rate which was around 5 µg/day. There is no appreciable burst release observed during the study, 
which probably resulted from the smaller surface to volume ration than micro-/nano- particles. 
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Additionally, PLGA-PTX-CHI implant contained chitosan in the implant, resulting a steadier 
and slower drug release and a stable pH medium, which inhibited PLGA autocatalytic 
degradation. 
3.4.3.2 Mass Loss of Implants. 
PLGA is hydrolytically degraded into smaller chain acids, and its final degradation 
products are lactic acid and glycolic acid. However, PLGA erosion is more complex than its 
degradation, since it not only depends on polymer degradation, but also involved in many 
physical change processes, including dissolution and diffusion of PLGA degradation products 
and swelling [45]. The drug compound in the polymer matrix may be released by some 
combination of diffusion through the polymer matrix, diffusion through pores, and dissolution 
coincident with polymer dissolution. To further understand the influence of PLGA erosion on 
PTX release, the mass loss was measured as an indicator of erosion. 
As shown in Figure 3.12, different drug formulations implants (PLGA implants and 
PLGA-CHI implants were studied as controls) display different mass loss profiles, which could 
be characterized by the mass loss rate (slope) and accumulated mass loss in 30 days. Nonlinear 
regression analysis of mass loss rate for each formulation of the implants is shown in Table 3.3 
(coefficient of determination R2 was comprised between 0.82 and 0.99) [46]. It is evident that the 
initial mass loss of PLGA-PTX and PLGA-PTX-CHI implants occurred after a lag phase (about 
2 weeks), and subsequently a rapid erosion process occurred in PLGA-PTX implants, while a 
slow depletion occurred in PLGA-PTX-CHI implants. Clearly, there was a significant difference 
in mass loss rate among the four formulations of the implants from day 18 to day 30 of in vitro 
release studies, where it is observed that PLGA and PLGA-PTX implants possess a much higher 
mass loss rate than both PLGA-CHI and PLGA-PTX-CHI implants, and that the PLGA-PTX-
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CHI implants displayed the lowest mass loss rate. Meanwhile, there was a significant effect of 
implant formulation on total mass loss percentage in 30 days at p < 0.05 level for four implants. 
Post hoc comparisons by Tukey HSD test indicated that the mean of total mass loss percentage 
for PLGA-PTX (Mean = 77.24, SD = 3.51) and PLGA (Mean = 75.80, SD = 3.89) implants were 
significantly different than the PLGA-CHI (Mean = 7.12, SD = 1.61) and PLGA-PTX-CHI 
(Mean = 4.14, SD = 0.33) implants. However, PLGA-CHI total mass loss percentage did not 
significantly differ from PLGA-PTX-CHI total mass loss percentage, and PLGA-PTX total mass 
loss percentage did not significantly differ from PLGA total mass loss percentage. These results 
suggest that introducing CHI into PLGA rod implants do cause an effect on polymer erosion. But 
loading PTX into the PLGA rod implants does not appear to significantly change the erosion 
rate. 
For PLGA-PTX implants, the erosion of PLGA had limited impact on the whole drug 
release behavior because the drug release occurred earlier than pronounced erosion. However, it 
seemed that drug release and mass loss for PLGA-PTX-CH happened almost simultaneously, 
and the release pattern was in good overall agreement with the mass loss curve. This result 
indicated that the PTX release from PLGA-PTX-CHI implant was mostly dominated by erosion.    
Hence, the released PTX in the medium of PLGA-PTX implants increased speedily, 
while it increased gradually in the medium of PLGA-PTX-CHI implants. Combined with the 
results from SEM morphological observations and the DSC thermographs, the PLGA and 
PLGA-PTX implants showed a typical bulk erosion degradation mechanism in in vitro. 
However, PLGA-CHI and PLGA-PTX-CHI implants exhibited that they degraded in a similar 
manner to surface erosion. A previous study about effect of different drugs on the degradation 
rate of PLGA matrices concluded that the drugs could affect the rate and the mechanism of 
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polymer implant degradation [47]. In our case, chitosan had an impact on the degradation profile 
of the PLGA implant compared with the control rods (PLGA and PLGA-PTX implant). 
According to Kiortsis et al. [48], it is reasonable that hydrophobic ingredients with low water 
solubility dispersed in PLGA will inhibit water penetration and diffusion into the matrix, 
consequently leading to a slow degradation and surface erosion.    
 
Figure 3.11 Plot of the percentage of accumulated PTX released of PLGA-PTX and PLGA-
PTX-CHI implants in in vitro release experiment. The data are expressed as mean± S.D. (n=3) 
 
 
Figure 3.12 Plot of the accumulated mass loss percent of each formulation implant in in vitro 
degradation experiment. The data are expressed as mean± S.D. (n=3) 
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Table 3.3 Nonlinear Regression Analysis of each formulation implant mass loss between 18th 
and 30th day 
 
 
Slope (Mass loss rate, % day−1) 
Drug composition 95% Confidence Interval 
 
 Estimate (Mean) Lower Upper 
Slope of PLGA 5.26 4.32 6.20 
Slope of PLGA-CHI 0.28 0.11 0.45 
Slope of PLGA-PTX 6.25 4.65 7.86 
Slope of PLGA-PTX-CHI 0.09 0.04 0.15 
 
 
3.4.4 pH change in degradation medium 
Since changes in pH levels have impact on human body functionality, such as 
immunological reactions [49], it is important to evaluate the pH level changes during implant 
degradation [49, 50]. As Liu et al. [51] presented in their work, accumulation of acidic implant 
degradation products may increase the risk of inflammation at the implant site. Hence, pH 
studies were conducted to examine the influence of chitosan on pH neutralization during drug 
release. The buffer pH was measured at each time point to profile the acidity changes in in vitro 
conditions of each formulation implants in 30 days. The studies were carried out in two slightly 
different situations, besides the same incubator settings, one was taken the procedures exactly 
same with in vitro drug release study, and the other was immersing the implants in 15ml PBS 
(pH 7.4) without refreshing PBS every day. Data were collected on a daily basis from triplicates 
of each formulation implant from day 0 to day 30 and plotted in Figure 3.13. Results from non-
refreshing PBS study revealed that the buffer pH value over the course of the study ranged from 
a pH 7.4 initially to an approximate pH 4.1 on day 30 for the PLGA implants, pH 4.3 for the 
PLGA-PTX implants, pH 7.1 for the PLGA-CHI implants, and pH 7.2 for the PLGA-PTX-CHI 
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implants, respectively. The decreased pH value occurred when too much acid was added to the 
buffer that they become the excess reactant. In this work, due to the accumulation of acidic 
degradation products of PLGA, the pH value of each implant degradation medium has shown 
different degrees of decline. According a one-way ANOVA results, it was found that the implant 
formulation had a significant effect on medium pH change. Post hoc comparisons by Tukey HSD 
test revealed that after 30 days, the mean of medium pH value for PLGA-PTX (Mean = 4.29, SD 
= 0.04) and PLGA (Mean = 4.09, SD = 0.01) implants were significantly different than the 
PLGA-CHI (Mean = 7.22, SD = 0.02) and PLGA-PTX-CHI (Mean = 7.12, SD = 0.03) implants.  
Due to the addition of buffer, the refreshing PBS study showed each formulation had a 
more stable curve for pH changes. PLGA and PLGA-PTX implants only dropped the medium 
pH value to 6.2 and 6.3, respectively, after 30 days. However, PLGA-CHI and PLGA-PTX-CHI 
implants both kept their medium pH value between 7.4 and 7.3. A one-way ANOVA on medium 
pH (value of pH over 30 days) from all formulations yielded significant difference (p < 0.05). 
Tukey post hoc analysis showed that PLGA implant was significantly different from the other 
three implants, so was PLGA-PTX implant; PLGA-CHI and PLGA-PTX-CHI implants did not 
differ significantly at p < 0.05. 
In general, from these pH studies, the pH value of release medium for PLGA and PLGA-
PTX implants started to decrease on day 17, and declined rapidly over the next 13 days, while 
the pH value of release medium for PLGA-CHI and PLGA-PTX-CHI implants both remained in 
a more stable range from 7.4 to 7.1. These findings were compatible with the mass loss results, 
which were that the PLGA and PLGA-PTX implants began to have apparent mass loss after day 
18 as a result of the formation of numerous soluble monomers and oligomers with acidic end-
groups yielding to a decrease in pH.  
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                        (a) 
 
 
                       (b) 
 
Figure 3.13 Plot of the pH change in PBS (pH 7.4) solvent. (a) pH change studies without 
refreshing medium in 30 days. (b) pH change studies with refreshing medium every day. The data 
are expressed as mean± S.D. (n=3) 
 
3.5    Conclusions 
Through this study, a novel method for fabricating PTX-loaded rod shape polymeric 
implants using cyromilling and injection molding was developed. This proposed drug delivery 
implant has been integrated PLGA with chitosan without any solvent by cryomilling, and proven 
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to provide a sustainable drug delivery with no burst release. The results obtained from in vitro 
release studies of four different formulation of implants showed that there was a decrease in the 
drug release rate of the chitosan blended formulations implants (PLGA-CHI and PLGA-PTX-
CHI) in PBS with pH of 7.4 in comparison with the formulations made of only PLGA as 
polymer matrix (PLGA and PLGA-PTX). Meanwhile, the pH change studies indicate that 
introducing chitosan in the PLGA implants could provide a relatively neutral and stable pH level 
during in vitro which could benefit the drug release. There is no doubt that by blending chitosan 
and PLGA to form a drug release matrix, a prolonged release of paclitaxel can be achieved. 
Nevertheless, further investigation of implants containing PLGA, chitosan and PTX on expanded 
in vitro studies with in vivo studies on rats with induced breast cancer is warranted.  
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CHAPTER 4                                                                                                                                   
GENERAL CONCLUSIONS 
4.1    Conclusions 
A review of literature on drug delivery systems for chemotherapy reveals that PLGA as a 
polymeric drug carrier for PTX has been extensively studied and its effectiveness proven. In this 
work, a process for fabrication of rod-shaped implants for delivery of PTX was well established. 
By cryomilling in a solid dispersion a homogenous blend of the natural polymer chitosan with 
PTX-loaded PLGA was obtained. The rod-shaped implants were then successfully made through 
injection molding. In vitro degradation studies showed that chitosan based PLGA drug implants 
could prolong the degradation and keep the degradation environment in a stable and neutral pH 
level. However, to fully understand the degradation profile of chitosan based rod-shaped 
implants, it is indispensable to conduct a longer in vitro experiment as well as in vivo experiment.  
 
4.2    Review of Contribution 
This thesis provides a unique and feasible method for fabricating an injectable rod-shaped 
implant composed of two immiscible polymers. Through cryomilling, chitosan could be 
homogenously blended in PLGA, resulting in a powder mixture, which can be easily molded to a 
rod shape by injection molding. This implant is intended to be placed in the human body 
subcutaneously or intramuscularly to provide a continuous release of drug over long periods of 
time. Hence, comparing to IV bag, it does not require repeated insertion of needles, which 
increases patient compliance. Introducing chitosan into PTX loaded PLGA implants can be used 
to regulate and adjust the degradation behavior of PLGA implants, thus the drug release could be 
controlled. 
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4.3    Future Perspectives 
In this study, the chitosan based implants yielded considerably slow drug release in vitro. 
However, further evaluation for their pharmacokinetics, degradation profile and influence on 
local pH in vivo is still needed because chitosan degradation mainly occurs by enzymatic 
depolymerization [1]. Also, different proportion of chitosan may result in different implant 
erosion and degradation speed, thus a customized drug release could be achieved depending on 
the ratio of ingredients. Besides, this drug delivery system could also be employed for the 
sustained release of other drugs and bioactive factors. 
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